A Prospective Study on the Prevalence of <scp>MASLD</scp> in Patients With Type 2 Diabetes and Hyperferritinaemia
Approximately 80% of people with hyperferritinaemia and T2DM have MASLD, and more than a third have significant hepatic fibrosis. Hyperferritinaemia may be a useful biomarker for MASLD and significant fibrosis in people with T2DM.
Authors
- Egbert Madamba (ORCID: https://orcid.org/0000-0002-4065-3538)
- Daniel Q. Huang (ORCID: https://orcid.org/0000-0002-5165-5061)
- Maral Amangurbanova (ORCID: https://orcid.org/0000-0002-3799-3857)
- Nabil Noureddin (ORCID: https://orcid.org/0000-0003-4770-119X)
- Scarlett Lopez
- Harris Siddiqi (ORCID: https://orcid.org/0000-0001-7434-9158)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Kaleb Tesfai (ORCID: https://orcid.org/0000-0001-5968-2294)
- Richelle Bettencourt
- Vanessa Cervantes (ORCID: https://orcid.org/0000-0002-5512-7493)
Institutions
- National University of Singapore (SG)
- University of California San Diego (US)
- National University Health System (SG)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/apt.18377
- Citations
- 19
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.35